Welcome to our dedicated page for Armata Pharmaceuticals SEC filings (Ticker: ARMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Armata Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Armata Pharmaceuticals's regulatory disclosures and financial reporting.
Armata Pharmaceuticals, Inc. reported that Chief Executive Officer Deborah Birx received a grant of stock options for 421,226 shares of common stock on March 9, 2026. The options carry an exercise price of 11.6100 per share and fully represent her derivative holdings after this grant.
According to the terms, 25% of the options vest on March 9 of each of 2027, 2028, 2029, and 2030, in each case conditioned on her continuous service through the relevant vesting date.
Armata Pharmaceuticals director Sarah J. Schlesinger reported a grant of 25,640 stock options. These options give her the right to buy 25,640 shares of Armata common stock at an exercise price of $11.61 per share and are held as a direct derivative position.
The options were awarded on March 9, 2026 as a compensation-related grant with no cash paid by her at grant. They will vest in full on March 9, 2027, as long as she continues to serve through that date, and are scheduled to expire on March 9, 2036 if not exercised.
Armata Pharmaceuticals director Jules Haimovitz received a grant of stock options to acquire 25,640 shares of common stock. The options have an exercise price of 11.61 per share and expire on March 9, 2036. They will vest in full on March 9, 2027, subject to continuous service through that date. Following this award, Haimovitz holds 25,640 stock options directly.
Armata Pharmaceuticals announced that the FDA has granted its intravenous S. aureus phage therapy candidate AP-SA02 Qualified Infectious Disease Product (QIDP) status for adjunct treatment of complicated bacteremia caused by MSSA or MRSA.
This QIDP designation provides five additional years of market exclusivity under the GAIN Act and makes AP-SA02 eligible for Fast Track consideration, priority review, and rolling review. Armata plans to request Fast Track designation and advance AP-SA02 into a planned Phase 3 superiority study in complicated S. aureus bacteremia, anticipated to start in the second half of 2026. Earlier Phase 1b/2a results were positive and development has been partially supported by a $26.2 million Department of Defense award.
Innoviva and its subsidiary report a controlling economic stake in Armata Pharmaceuticals. As of this amendment, they may be deemed to beneficially own 55,467,459 shares of Common Stock, or about 83.1% of Armata’s outstanding Common Stock on an as-converted and as-exercised basis.
This total includes 25,076,769 shares currently outstanding, 10,653,847 shares issuable from warrants, and 19,736,843 shares issuable upon conversion of a secured convertible loan. On January 23, 2026, Armata and Innoviva entities also extended the maturity of several credit agreements to June 1, 2027, pushed the expiration of multiple warrants to January 26, 2031, and updated the expiration terms of a voting agreement to the earlier of January 26, 2031 or U.S. FDA approval of any Armata product candidate.
Armata Pharmaceuticals updated key financing and governance arrangements with its principal shareholder Innoviva. The company amended four existing credit agreements with Innoviva Strategic Opportunities LLC to extend each loan’s maturity date to June 1, 2027, giving Armata more time before repayment is due.
The two parties also amended four existing warrant certificates held by Innoviva Strategic Opportunities LLC, pushing each warrant’s expiration date out to January 26, 2031. These warrants cover specific blocks of common stock, including 1,807,396 shares under a February 9, 2022 warrant and 4,285,935 shares under a March 17, 2021 warrant.
In addition, Armata, Innoviva and Innoviva Strategic Opportunities LLC modified their Second Amended and Restated Voting Agreement so that it now ends on the earlier of January 26, 2031 or approval by the U.S. Food and Drug Administration of any Armata product candidate for marketing and commercial distribution.
Armata Pharmaceuticals reported that it has received an End-of-Phase 2 written response from the U.S. Food and Drug Administration and plans to advance its intravenously administered Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study. The planned trial will focus on patients with complicated S. aureus bacteremia, a serious bloodstream infection.
The company disclosed this update through a press release furnished as an exhibit, emphasizing that the information is being provided for informational purposes and is not deemed filed under securities laws. No financial results or transaction details are included in this report.
Armata Pharmaceuticals, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC to set up an at-the-market stock offering program. Under this arrangement, Armata may, at its discretion, offer and sell shares of its common stock with an aggregate offering price of up to $100,000,000 through JonesTrading as sales agent. Sales can be made on the NYSE American or other permitted markets and in negotiated transactions, with Armata paying JonesTrading a commission of up to 3.0% of gross sale proceeds and reimbursing certain legal expenses. Neither party is obligated to sell or purchase shares, and the program is limited by the amount registered on Armata’s existing Form S-3 shelf registration and the number of authorized but unissued shares.
Armata Pharmaceuticals is launching an at-the-market offering of up to $100,000,000 of common stock through JonesTrading under a Capital on Demand Sales Agreement. JonesTrading will act as sales agent or principal and receive up to 3.0% commission on gross proceeds.
Based on a recent NYSE American price of $7.10 per share, the company illustrates issuance of about 14.1 million shares, which would raise $100.0 million and increase shares outstanding from 36,406,905 to up to 50,491,412. Armata plans to use net proceeds for working capital and general corporate purposes.
The company highlights substantial doubt about its ability to continue as a going concern and a need for significant additional financing, so this program adds flexible access to equity but could cause immediate and substantial dilution. Innoviva, Inc. beneficially owns more than 50% of the common stock, making Armata a controlled company.
Armata Pharmaceuticals (ARMP) filed its Q3 2025 10-Q reporting a net loss of $26.7M on grant and award revenue of $1.2M. Operating expenses were $8.9M, driven by R&D of $5.8M and G&A of $3.1M. Interest expense was $4.3M, and a change in fair value loss on the Convertible Loan added $14.6M to other expense.
Cash and cash equivalents were $14.8M at September 30, 2025. The company states that existing cash will not fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern. Current liabilities were $140.0M, including term debt current of $83.0M and the Convertible Loan at $48.1M measured at fair value. Total liabilities were $185.1M and stockholders’ deficit was $(95.6M).
Financing activity included a $10.0M loan on March 12, 2025 at 14% maturing March 12, 2026, and a $15.0M loan on August 11, 2025 at 14% maturing January 11, 2029, both secured by substantially all assets. Shares outstanding were 36,329,842 as of November 4, 2025.